139 related articles for article (PubMed ID: 31216160)
1. [Advances in the genetic abnormalities involved in the pathogenesis of acute myeloid leukemia].
Arbelbide JA
Rev Fac Cien Med Univ Nac Cordoba; 2019 Jun; 76(2):77-78. PubMed ID: 31216160
[No Abstract] [Full Text] [Related]
2. [FLT3 inhibitors for acute myeloid leukemia].
Kiyoi H
Nihon Rinsho; 2014 Jun; 72(6):1035-41. PubMed ID: 25016800
[TBL] [Abstract][Full Text] [Related]
3. Closing in on targeted therapy for acute myeloid leukaemia.
The Lancet Haematology
Lancet Haematol; 2019 Jan; 6(1):e1. PubMed ID: 30612709
[No Abstract] [Full Text] [Related]
4. Highlights in Hematologic Malignancy Treatments: Leukemia, Myelodysplastic Syndromes, and Allotransplant-New Drugs on the Horizon for Acute Myeloid Leukemia.
Jurcic JG
JAMA Oncol; 2017 Mar; 3(3):299-300. PubMed ID: 27787556
[No Abstract] [Full Text] [Related]
5. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
6. FLT3 inhibitors for acute myeloid leukemia.
Lancet JE
Clin Adv Hematol Oncol; 2015 Sep; 13(9):573-5. PubMed ID: 26452187
[No Abstract] [Full Text] [Related]
7. FLT3 inhibitors in acute myeloid leukemia: Current and future.
Thomas CM; Campbell P
J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation.
Best-Aguilera C; Rodrigo Gómez-Vázquez O; Elizabeth Guzmán-Hernández A; Monserrat Rojas-Sotelo R
Curr Oncol Rep; 2017 Mar; 19(3):21. PubMed ID: 28283965
[TBL] [Abstract][Full Text] [Related]
9. Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation.
Lee SH; Paietta E; Racevskis J; Wiernik PH
Am J Hematol; 2009 Oct; 84(10):701-2. PubMed ID: 19714594
[No Abstract] [Full Text] [Related]
10. Midostaurin in FLT3-mutated acute myeloid leukaemia.
Das M
Lancet Oncol; 2017 Aug; 18(8):e439. PubMed ID: 28669736
[No Abstract] [Full Text] [Related]
11. The Future of Targeting FLT3 Activation in AML.
Leick MB; Levis MJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy.
Schroeder T; Zohren F; Saure C; Bruns I; Czibere A; Safaian NN; Fenk R; Haas R; Kobbe G
Acta Haematol; 2010; 124(3):153-9. PubMed ID: 20938170
[No Abstract] [Full Text] [Related]
13. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
Garcia JS; Percival ME
Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
[TBL] [Abstract][Full Text] [Related]
14. FLT3 inhibitors for the treatment of acute myeloid leukemia.
Wiernik PH
Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy of acute myeloid leukemia in 2012: towards individualized therapy.
Foran JM
Hematology; 2012 Apr; 17 Suppl 1():S137-40. PubMed ID: 22507802
[TBL] [Abstract][Full Text] [Related]
16. Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.
Scholl S; Spies-Weisshart B; Klink A; Muegge LO; Fricke HJ; Hochhaus A
Ann Hematol; 2011 Apr; 90(4):473-5. PubMed ID: 20652568
[No Abstract] [Full Text] [Related]
17. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
Alachkar H; Mutonga M; Malnassy G; Park JH; Fulton N; Woods A; Meng L; Kline J; Raca G; Odenike O; Takamatsu N; Miyamoto T; Matsuo Y; Stock W; Nakamura Y
Oncotarget; 2015 Oct; 6(32):33410-25. PubMed ID: 26450903
[TBL] [Abstract][Full Text] [Related]
18. The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia.
Fathi AT; Chen YB
Eur J Haematol; 2017 Apr; 98(4):330-336. PubMed ID: 28000291
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
Naqvi K; Konopleva M; Ravandi F
Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia.
Mohan BP; How GF; Loh Y; Linn YC
Br J Haematol; 2012 Apr; 157(1):131-2. PubMed ID: 22050655
[No Abstract] [Full Text] [Related]
[Next] [New Search]
